Provenge Scores In Phase III; Will Dendreon Need To Confirm The IMPACT?
Executive Summary
Dendreon's release of positive Phase III results for immunotherapeutic Provenge - including a four-month overall survival benefit compared to placebo - begs the question of whether FDA will now approve the prostate cancer vaccine without a confirmatory trial
You may also be interested in...
Dendreon Readies For Next Provenge Hurdles: Supply And Reimbursement
Having gotten over the hurdle of FDA approval with the market's first therapeutic cancer vaccine, Dendreon now faces the challenge of getting Provenge to the market. Already the company is also signaling that supply is unlikely to match demand in the near term
Dendreon Readies For Next Provenge Hurdles: Supply And Reimbursement
Having gotten over the hurdle of FDA approval with the market's first therapeutic cancer vaccine, Dendreon now faces the challenge of getting Provenge to the market. Already the company is also signaling that supply is unlikely to match demand in the near term
Dendreon Set To Ship Provenge Within A Week
Demand expected to exceed supply as company builds manufacturing capacity.